CIK 0001662774
- Non-accelerated filer
- Smaller reporting company
IRulya Therapeutics Inc.
Sign in to watch- Ticker
- IRLA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 901024039
- Phone
- +1 203-208-8994
- Business address
- 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
- Former names
- Quince Therapeutics, Inc., Cortexyme, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-05-13 | Lamond David Director | Conversion · Series A Redeemable Convertible Preferred Stock | −699,280 | 0 | ||
| 2019-05-13 | Lamond David Director | Conversion · Series A Redeemable Convertible Preferred Stock | −301,829 | 0 | ||
| 2019-05-13 | Lamond David Director | Conversion · Series B Redeemable Convertible Preferred Stock | −924,056 | 0 | ||
| 2019-05-10 | EPIQ Capital Group, LLC IA/Managing Member of 10% owne | Purchase | +4,350 | $26.41 | $115K | 2,835,560 |
| 2019-05-10 | EPIQ Capital Group, LLC IA/Managing Member of 10% owne | Purchase | +4,170 | $27.58 | $115K | 2,839,730 |
| 2019-05-10 | EPIQ Capital Group, LLC IA/Managing Member of 10% owne | Purchase | +80 | $27.05 | $2K | 2,839,810 |
| 2019-05-10 | EPIQ Capital Group, LLC IA/Managing Member 10% owner | Purchase | +4,350 | $26.41 | $115K | 2,822,546 |
| 2019-05-10 | EPIQ Capital Group, LLC IA/Managing Member 10% owner | Purchase | +4,170 | $27.58 | $115K | 2,826,716 |
| 2019-05-10 | EPIQ Capital Group, LLC IA/Managing Member 10% owner | Purchase | +80 | $27.05 | $2K | 2,826,796 |
| 2019-05-08 | McLoughlin Margaret Director | Grant or award · Stock Option (Right to buy) | +91,911 | 91,911 |
Page 18 of 18 · 350 trades